Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability
Journal of Thrombosis and Haemostasis2017Vol. 15(11), pp. 2147–2157
Citations Over TimeTop 10% of 2017 papers
Jacqueline ML Halton, Manuela Albisetti, Branislav Biss, Lisa Bomgaars, Martina Brueckmann, Savion Gropper, Ruth Harper, Fenglei Huang, Matteo Luciani, Hugo Maas, Igor Tartakovsky, Lesley Mitchell
Related Papers
- → The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples(2013)83 cited
- Adherence, persistence, and switching patterns of dabigatran etexilate.(2013)
- → Dabigatran in Clinical Practice for Atrial Fibrillation With Special Reference to Activated Partial Thromboplastin Time(2012)30 cited
- → Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation(2014)29 cited
- → Dabigatran Versus Warfarin in Atrial Fibrillation(2014)12 cited